COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Vilya operates a proprietary ML and generative‑AI computational drug‑design platform to create de novo, membrane‑permeable macrocycles between small molecules and antibodies, advancing a pipeline targeting difficult protein–protein interactions.
